{"filings":[{"id":1232079,"accession_number":"0001411690-26-000040","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-06-24T12:30:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bionano Genomics hires Alex Hastie, Ph.D., as Chief Scientific Officer effective July 20, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hastie returns after 14 years at Bionano as a foundational figure in optical genome mapping (OGM) technology.","He will lead global scientific strategy, innovation roadmap, and research initiatives for genome analysis.","Quotes from experts at Radboud, Johns Hopkins, MD Anderson, and Dartmouth welcome his return as 'Mr. OGM'.","Appointment underscores Bionano's commitment to advancing OGM for clinical and research applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":887958,"accession_number":"0001411690-26-000036","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-06-05T20:00:16+00:00","items":["5.02"],"status":"ready","headline":"Bionano Genomics CMO Alka Chaubey resigns effective July 5, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alka Chaubey, Ph.D. resigned as Chief Medical Officer on June 2, 2026.","Her resignation becomes effective July 5, 2026.","No replacement or reason for departure was disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":705279,"accession_number":"0001411690-26-000033","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-28T12:00:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bionano retires all $20M senior secured convertible debentures, eliminating secured debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Retired $20M in senior secured convertible debentures using cash on hand on May 26, 2026.","All liens on company's assets released and restrictive covenants extinguished.","Company now has no outstanding secured debt obligations, providing greater financial flexibility.","Debentures originally issued in May 2024; retirement completes the debt restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443438,"accession_number":"0001411690-26-000030","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-14T20:29:23+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders elect Luderer and Vuori as directors; pay vote and auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Albert Luderer (847,601 for) and Kristiina Vuori (867,474 for) as Class II directors for three-year terms.","Advisory vote on named executive officer compensation passed with 697,999 for, 216,553 against, 76,839 abstentions.","Ratification of BDO USA as independent auditor for fiscal 2026 passed with 3,770,715 votes for, 206,541 against.","Quorum was 38.1% of 11,091,615 shares outstanding (4,225,995 shares present).","Broker non-votes totaled 3,234,604 on director elections and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67885,"accession_number":"0001411690-26-000027","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-13T20:03:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q1 revenue $6.7M (+4% YoY); gross margin 49%; positive coding updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.7M (+4% vs $6.5M Q1 2025); consumables revenue $3.9M (+20%).","Gross margin improved to 49% from 46% YoY; sold 8,178 nanochannel flow cells (+17%).","Operating expenses cut 2% to $11.1M; adjusted op. expense +7% to $9.1M.","New CPT code 81354 for OGM in constitutional genetics effective Jan 1, 2026, priced above microarray codes.","Final CLFS shows 47% payment increase for CPT 81195 (OGM in hematologic malignancy) to $1,853.22."],"consensus_eps_estimate":-0.969,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":6687000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92709,"accession_number":"0001411690-26-000019","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bionano Genomics CEO Erik Holmlin terminated; Chairman Al Luderer named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Erik Holmlin terminated effective May 5, 2026; will serve as advisor under consulting agreement.","Board appoints Chairman Albert Luderer as interim CEO and interim principal financial officer.","Luderer receives $600k base salary, up to $400k bonus, and $4k/month housing/travel stipend.","Chris Twomey appointed Lead Independent Director to support governance during transition.","Company will immediately commence search for a permanent CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103759,"accession_number":"0001411690-26-000006","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q4 2025 revenue $8.0M (-3% YoY); FY revenue $28.5M (-7%)","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2025 revenue $8.0M vs $8.2M Q4 2024; consumables/software revenue down 1%.","Full-year 2025 revenue $28.5M vs $30.8M FY2024; consumables/software up 7%.","Q4 gross margin 43% (42% prior); non-GAAP gross margin also 43%.","Operating expenses reduced 22% to $11.9M in Q4; installed base 387 systems (+4%).","Company provided 2026 revenue outlook (specific figures not available in excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103758,"accession_number":"0001140361-26-000904","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano reports preliminary Q4/FY 2025 revenue down 2-8% YoY; cash $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total Q4 revenue $7.8-8.0M, down 2-4% YoY; full-year $28.4-28.6M, down 7-8%.","Installed 9 new OGM systems in Q4, 32 in FY; installed base at 387 systems at year-end.","Cash, equivalents and restricted investments $29.6M as of Dec 31, 2025 ($10.3M restricted).","Nanochannel array flowcells sold: 7,554 in Q4, 30,171 for full year 2025.","Preliminary unaudited results; subject to change after year-end close and audit."],"consensus_eps_estimate":-1.428,"consensus_eps_actual":-4.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":28508000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120017,"accession_number":"0001411690-25-000092","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q3 revenue $7.4M (+21% YoY); raises FY 2025 OGM install guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.4M, up 21% from $6.1M in Q3 2024; consumables/software revenue +15%.","GAAP gross margin 46% vs (139)% a year ago; non-GAAP gross margin 46% vs 26%.","Operating expenses cut 66% to $11.9M; cash and investments $31.8M at quarter-end.","Raised FY 2025 OGM system install guidance to >25 units (prior 20-25).","Reiterated FY 2025 revenue guidance $26-30M; Q4 2025 revenue guided $7.5-7.9M."],"consensus_eps_estimate":-1.9482,"consensus_eps_actual":-4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":20557000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136579,"accession_number":"0001140361-25-035286","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics closes $10M public offering of 5M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10M from sale of 5M shares and Series E/F warrants to purchase up to 10M shares.","Net proceeds approximately $9.0M after placement agent fees and offering expenses.","Warrants exercisable at $2.00 per share; Series E expire in 5 years, Series F in 18 months.","Proceeds to be used for working capital and general corporate purposes.","Offering closed on September 17, 2025; H.C. Wainwright acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136578,"accession_number":"0001411690-25-000082","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.","Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.","Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).","Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026."],"consensus_eps_estimate":-2.4633,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":13190000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153767,"accession_number":"0001411690-25-000077","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K/A","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics corrects vote counts for Proposals 3 and 4; results unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected Broker Non-Votes for Proposal 3 from 769,744 to 0; no impact on ratification of BDO USA as auditor.","Corrected Broker Non-Votes for Proposal 4 from 0 to 769,944; vote outcome unchanged.","Corrected Votes For on Proposal 4 from 369,176 to 396,176; still approved.","All shareholder vote outcomes remain the same per the original June 13, 2025 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153769,"accession_number":"0001411690-25-000073","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"BNGO holds annual meeting, re-elects directors, approves share issuance, appoints Vuori to audit committee","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kristiina Vuori appointed to Audit Committee effective June 10, 2025.","Holmlin and Barker elected as Class I directors with 377,358 and 382,707 votes for, respectively.","Advisory vote on executive compensation approved with 375,470 for, 328,513 against, showing notable dissent.","Ratification of BDO USA as auditor approved (1,304,265 for vs 99,528 against).","Issuance of up to 661,374 shares upon exercise of purchase warrants approved (369,176 for, 311,661 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153768,"accession_number":"0001411690-25-000045","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.","Flowcell sales 6,994 units (-15% YoY); to routine customers up 1% after adjusting for new adds.","GAAP operating expense $11.4M, down 66% YoY from cost cuts and restructuring.","Cash, equivalents and investments $29.2M; cash runway extended into Q1 2026.","FY2025 revenue guidance updated to $26-30M; Q2 revenue expected $6.3-6.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172459,"accession_number":"0001411690-25-000036","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.","GAAP gross margin improved to 42% from 23% YoY; GAAP operating expense cut to $15.4M from $27.4M.","Full-year product revenue $27.0M (+1% YoY) with consumables +14% and software +11%; instruments down ~$2M.","Installed OGM systems 371 (+14% YoY); flowcell sales 30,307 (+15% YoY); 336 OGM publications in 2024.","Cash & securities $20.9M at year-end (incl. $11.4M restricted); raised $10M in Jan 2025 offering; modified debentures to reduce payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6457000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172458,"accession_number":"0001140361-25-005427","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bionano Genomics enters new $75M ATM sales agreement with H.C. Wainwright, replacing Cowen facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated prior Cowen sales agreement effective Feb 14, 2025; suspended offering Feb 4.","New ATM with H.C. Wainwright allows sale of up to $75M of common stock at market prices.","Wainwright receives 3.0% commission on gross proceeds from each sale.","Shares sold on Nasdaq through at-the-market offerings; company may suspend at any time.","Registration statement on Form S-3 effective May 10, 2023, covering the new facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172457,"accession_number":"0001140361-25-003762","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Bionano Genomics terminates $200M ATM equity facility with Cowen, effective Feb 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Sales Agreement with Cowen and Company effective Feb 14, 2025.","Agreement allowed sale of up to $200M in common stock via ATM program.","Company provided notice on Feb 4, 2025; no reason disclosed for termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172456,"accession_number":"0001411690-25-000008","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Bionano Genomics effects 1-for-60 reverse stock split effective Jan 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:60, effective 5:00 p.m. ET on January 24, 2025.","Common stock begins trading split-adjusted on Nasdaq Capital Market under BNGO on Jan 27.","No fractional shares issued; stockholders entitled to fractional shares receive cash in lieu.","Proportionate adjustments to stock options, RSUs, warrants, and convertible debentures exercise prices and share counts.","New CUSIP number for common stock post-split: 09075F404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172455,"accession_number":"0001411690-25-000005","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders approve reverse stock split (1:25-1:75) and warrant share issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Jan 15 special meeting, stockholders approved issuance of up to 19,762,226 shares upon exercise of Series C/D warrants.","Proposal 2 approved reverse stock split at ratio between 1-for-25 and 1-for-75, with exact ratio to be set by Board.","Approvals required for Nasdaq listing compliance and to maintain stock price above minimum bid.","Votes: Proposal 1 – 7.1M for, 3.3M against, 6.7M abstain, 25.3M broker non-votes.","Votes: Proposal 2 – 29.0M for, 12.8M against, 0.6M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172454,"accession_number":"0001411690-25-000003","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.","Full year 2024 revenue $30.5-30.7M, down ~15% from FY2023; excluding discontinued services, core revenue ~$29M, roughly flat.","OGM installed base 371 units at year-end, up 14% from 326 at end of 2023; flowcell sales 8,058, up 1% YoY.","Cash, equivalents and AFS securities $20.9M as of Dec 31, 2024; raised $10M gross via registered direct offering in Jan 2025.","Annualized operating costs reduced by ~$100M since May 2023; senior secured convertible debenture terms modified to lower monthly payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-88.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":30776000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172453,"accession_number":"0001140361-25-000296","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics raises $10M in registered direct offering of ~39.7M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds of ~$10M from sale of 22.9M common shares and 16.78M pre-funded warrants at $0.252/unit.","Each share/pre-funded warrant includes a purchase warrant exercisable at $0.252; warrants require stockholder approval, expire in 5 years.","Closing expected on January 6, 2025; H.C. Wainwright serves as placement agent with 6% cash fee.","Net proceeds to be used for working capital, R&D, debt repayment or redemption, and capital expenditures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172452,"accession_number":"0001140361-25-000132","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Bionano Genomics amends convertible debentures, reduces near-term payments, conversion price to $0.27","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment defers December 2024 redemption; monthly payments cut from $1M to $500k for Jan-Jul 2025, then rise to $1.375M from Aug 2025.","Conversion price reduced from $2.00 to $0.27; $15M principal convertible into 55.6M shares; 45.6M unregistered.","Company issued 5M shares as consideration; forbears from redemption notices until July 31, 2025.","Company to file registration statement for resale of shares by Jan 7, 2025.","Canaccord Genuity acted as exclusive financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189455,"accession_number":"0001411690-24-000066","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders approve issuance of up to 35M shares upon warrant exercise","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vote passed: 22.9M for, 6.2M against, 1.4M abstentions, no broker non-votes.","Approval covers Series A and B warrants from July 4, 2024 private placement to institutional investors.","Issuance required for Nasdaq Listing Rule 5635(d) compliance; warrants were already outstanding.","Potential dilutive impact: up to 35M shares vs. ~86M outstanding as of August 12, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189454,"accession_number":"0001411690-24-000060","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q3 revenue $6.1M (-35% YoY); GAAP gross margin -139% on $9.8M impairment; cash burn down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.1M (-35% YoY); core product/software sales $6.6M offset by $0.5M receivable write-down from discontinued clinical services.","GAAP gross margin (139)% vs 30% YoY due to $9.8M impairment/disposal of reagent rentals and inventory; non-GAAP margin 26%.","GAAP operating expense $35.5M; non-GAAP $16.1M (-49% YoY). Cash, securities & restricted cash $23.4M as of Sept 30.","Installed base 368 OGM systems (+22% YoY); 7,835 flowcells sold (+27% YoY). Raised $10M upfront from registered direct offering & warrants Q3, plus $3M post-Q3.","Special meeting adjourned for lack of quorum; reconvenes Nov 27. CPT code for OGM in blood cancers expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":22613000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189453,"accession_number":"0001140361-24-044715","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Bionano Genomics raises ~$3M in registered direct offering of 9.9M shares and warrants at $0.3039/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 9,881,113 shares of common stock and Series C/D warrants to purchase up to 9,881,113 shares each at $0.3039 per share.","Gross proceeds of $3M from offering, with potential additional $6M if warrants fully exercised on cash basis.","Closing expected on October 31, 2024; H.C. Wainwright acted as exclusive placement agent with 6% cash fee.","Net proceeds to be used for working capital, R&D, repayment or redemption of existing indebtedness, and capex.","Warrants exercisable only after stockholder approval; Series C expires in 5 years, Series D in 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189452,"accession_number":"0001140361-24-043244","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano lowers Q3 revenue guidance to $6.5-6.8M from $7.9-8.9M; cash $23.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q3 revenue $6.5-6.8M, down from prior guidance of $7.9-8.9M.","Cash and restricted cash ~$23.3M as of Sep 30; $11.4M restricted.","Revenue miss driven by strategic shift away from new OGM system placements and sector headwinds.","Potential material impairments and charges pending completion of end-of-period review."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":22613000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205962,"accession_number":"0001140361-24-040508","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.","Revenue guidance reduced to $32-36M from $36-40M due to fewer OGM instrument placements.","CFO Gülsen Kama leaving effective Sep 18; CEO Erik Holmlin appointed principal financial officer.","Restructuring charges estimated at $0.5-1.0M, substantially complete by Oct 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205961,"accession_number":"0001411690-24-000046","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q2 revenue $7.8M (-10% YoY); FY2024 guidance $36-40M; retires $15.3M notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.8M, down 10% YoY; GAAP gross margin 33% vs 27% in Q2 2023.","GAAP operating expense $19.6M, down 53% YoY; non-GAAP $18.8M, down 46%.","Cash and securities $30.3M as of June 30, with $11.4M restricted; $20M in debentures outstanding.","Retired $15.3M convertible notes for $17.6M redemption plus $2.2M fee, funded by $18M private placement of senior secured convertible debentures.","Guides full year 2024 revenue $36-40M; Q3 2024 revenue expected $7.9-8.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":16540000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205960,"accession_number":"0001411690-24-000044","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bionano Genomics receives Nasdaq notice for bid price below $1.00; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Bionano on July 12, 2024 that its stock closed below $1.00 for 30 consecutive trading days.","Company has 180 calendar days to regain compliance; closing bid price must be at least $1.00 for 10 consecutive business days.","If non-compliance persists, Bionano may seek an additional 180-day period if it meets other listing standards.","Stock continues trading on Nasdaq Capital Market under symbol BNGO; delisting possible if not cured.","Bionano intends to monitor the bid price and may consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205959,"accession_number":"0001140361-24-032559","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Bionano raises $10M upfront via registered direct offering; adds $20M potential from milestone warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17.5M shares/equivalents sold at $0.571/share for gross proceeds of ~$10M.","Concurrent private placement includes Series A & B warrants exercisable at $0.571/share, offering up to $20M additional.","Series A warrants expire 24 months post-stockholder approval or 60 days after MolDX coverage for optical genome mapping.","Series B warrants expire 5 years post-approval or 6 months after FDA clearance for optical genome mapping system.","Net proceeds earmarked for working capital, R&D, debt repayment, and capex; closing expected July 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222977,"accession_number":"0001411690-24-000040","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano Genomics stockholders elect three Class III directors, approve say-on-pay, ratify auditor at 2024 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Christopher Twomey, Yvonne Linney, and Aleksander Rajkovic as Class III directors until 2027.","Advisory vote on executive compensation approved: 9,508,999 for, 1,771,611 against, 642,388 abstentions.","Ratification of BDO USA as independent auditor for FY 2024 approved: 26,950,772 for, 2,788,563 against, 308,349 abstentions.","Approximately 44.94% of outstanding shares (30,047,684) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222976,"accession_number":"0001140361-24-027553","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Bionano raises $18M via convertible debt, retires High Trail Note, warns of going concern","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $20M principal senior secured convertible debentures (11% interest, due 2026) plus 2.25M shares for $18M gross proceeds.","Used ~$17.6M to redeem High Trail Note (outstanding $15.337M at 115% redemption, plus $2.19M retirement fee); Note cancelled.","Debentures convertible at $2.00/share; Company must maintain $11M blocked account; monthly redemption up to $1M allowed.","Cash runway only into Q4 2024; substantial doubt about going concern exists; board formed strategy committee for alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222975,"accession_number":"0001411690-24-000020","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Bionano Q1 revenue $8.8M (+18% YoY); cash burn down 41% YoY; restructuring charges $4.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $8.8M, +18% YoY; GAAP gross margin 32% vs 28% in Q1 2023.","Operating cash burn (excl. interest/debt) $19M in Q1 2024, down from $32M in Q1 2023.","Reaffirmed FY2024 revenue guidance of $37-41M; Q2 2024 revenue expected $7.8-8.2M.","Installed base of 347 OGM systems (+34% YoY); flowcell sales up 58% to 8,249 units.","Restructuring charges of ~$4.6M from March 2024 RIF; substantially complete by June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":8769000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222974,"accession_number":"0001140361-24-018645","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bionano Genomics files $8.7M registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 6,536,682 common shares, pre-funded warrants for 2,196,944 shares, and warrants for 8,733,626 shares.","Pre-funded warrants allow purchase of common stock at a nominal exercise price; warrants have exercise price and term set in prospectus.","Legal opinion from Cooley LLP on validity of shares and warrant shares filed as Exhibit 5.1.","Proceeds intended for general corporate purposes; no specific pricing or discount disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222973,"accession_number":"0001140361-24-018181","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bionano Genomics raises $10M via registered direct offering of common stock and warrants at $1.145/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 8.73M shares (or equivalents) and warrants to purchase 8.73M shares at $1.02; exercise price $1.02, 5-year term.","Gross proceeds ~$10M; net proceeds for working capital, R&D, debt repayment, and capex.","Expected closing on April 8, 2024; H.C. Wainwright acts as sole placement agent with 6% cash fee.","Offered under effective shelf registration statement (File No. 333-270459); warrants include beneficial ownership limitations of 4.99%/9.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242462,"accession_number":"0001411690-24-000004","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2023 revenue $10.7M, FY 2023 revenue $36.1M, both up 30% YoY.","GAAP gross margin Q4 23%, FY 26% (up from 21% in 2022).","Plans to cut 110-125 employees (34-39% of workforce) and phase out testing services generating 19.4% of FY 2023 revenue.","Restructuring expected to yield $35-40M annual operating expense savings starting H2 2024.","No specific 2024 revenue guidance provided; cash and securities $102.3M at year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242461,"accession_number":"0001140361-24-009930","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bionano amends convertible debt deal, redeems $27.7M of notes, cuts liquidity covenant to $25M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeems entire $17M outstanding principal of Initial Private Placement Note at 115% for $19.55M; plus $1M increase to retirement fee.","Redeems $10.663M of Initial Registered Note at 115% for $12.26M; $24.337M principal remains outstanding.","Minimum liquidity covenant reduced from $50M to $25M; restricted cash requirement cut from $35M to $25M.","March 2024 partial redemption canceled; April payment delayed from April 1 to April 20, 2024.","Company gains immediate access to $30M in near-term liquidity, with up to $25M more as principal is retired."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242460,"accession_number":"0001140361-24-001200","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano prelim Q4 rev $10.4-10.7M (+27-30% YoY); OGM base 326 (+36%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Prelim Q4 2023 rev $10.4-10.7M vs $8.2M Q4 2022; FY rev $35.8-36.1M (+29-30%).","OGM installed base 326 as of year-end 2023, up 36% from 240 in 2022.","Q4 flowcell sales 7,980, up 67% from 4,781 in Q4 2022.","Cash, equivalents & securities ~$102.8M at Dec 31, 2023; $36.1M restricted.","Raised net $11.0M from ATM in Nov-Dec 2023 and $2.9M additional in Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":36116000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259855,"accession_number":"0001140361-23-054553","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Bionano Genomics files updated legal opinion to increase ATM shares capacity to 149M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updated legal opinion from Cooley LLP covers up to 149M shares under ATM sales agreement with Cowen.","Prior opinion covered 49M shares; new opinion triples authorized shares for at-the-market offerings.","Update required to maintain ATM program access under terms of $80M senior secured convertible notes issued in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259854,"accession_number":"0001411690-23-000080","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Bionano Q3 revenue $9.3M (+29% YoY); $80M convertible notes completed; $33M cost savings plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $9.3M, +29% YoY; GAAP gross margin 30% vs 25% YoY; non-GAAP operating expense $31.8M.","Completed $80M convertible notes offering (Oct 13), extending cash runway; cash & securities $63.6M.","Cost reduction initiatives expected to save ~$33M annually starting 2024; reiterated FY2023 rev guidance $35-$38M.","Saphyr installed base 301 (+39% YoY); flowcells sold 6,176 (+55% YoY); OGM publications up 61% YoY.","Appointed Gülsen Kama as CFO effective Sept 11, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":25395000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259853,"accession_number":"0001140361-23-047688","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["1.01","2.02","2.03","2.05","3.02","7.01","9.01"],"status":"ready","headline":"Bionano Genomics closes $80M convertible note financing with High Trail; plans 17% workforce reduction","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered securities purchase agreement to issue $45M registered and $35M private senior secured convertible notes due 2025; warrants to buy up to 21.66M shares at $3.1855.","Net proceeds estimated at $75.6M; proceeds used for working capital and general corporate purposes including R&D and capex.","Reduces headcount by ~66 employees (17% of full-time staff) as part of corporate reorganization to save ~$33M annually starting 2024.","Notes carry initial conversion price of ~$2.8638 per share; no regular interest; repayment at 115% of principal at maturity.","Issued press release announcing preliminary Q3 2023 results; specific figures not provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277116,"accession_number":"0001140361-23-039417","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Bionano Genomics appoints Gülsen Kama as CFO effective September 11, 2023; Chris Stewart resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kama's base salary set at $460,000/year with 55% target bonus; receives option for 106,000 shares vesting over 4 years.","Kama also gets a one-time $150,000 signing bonus contingent on one year of continuous employment.","Stewart's severance includes lump sums equal to six weeks base salary, additional six weeks upon strategic milestone, and six months base salary cash.","Stewart will consult at $500/hour through November 11, 2023, with equity vesting continuing during consulting period.","Kama previously served as CFO of Northern Data AG and East Region & Healthcare IT CFO at Quest Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277115,"accession_number":"0001411690-23-000067","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Genomics Q2 revenue up 30% to $8.7M; flowcell sales more than double YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue $8.7M, +30% YoY; GAAP gross margin 27% vs 22%.","Installed Saphyr systems 281 (+43% YoY); flowcells sold 7,062 (+108% YoY).","GAAP operating expense $41.5M vs $33.6M; non-GAAP opEx $34.6M.","Cash & securities $77.1M at June 30, down from $95.8M at March 31.","Announced Stratys high-throughput OGM system and VIA software for hematologic malignancies."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":16077000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277114,"accession_number":"0001140361-23-038095","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Bionano Genomics effects 1-for-10 reverse stock split, effective August 4, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:10 effective 5:00 p.m. ET on August 4, 2023; trading on split-adjusted basis begins August 7, 2023.","No fractional shares issued; stockholders otherwise entitled to fractional share receive cash in lieu.","Proportionate adjustments to per-share exercise price and shares of stock options, RSUs, and warrants.","Certificate of Elimination filed for Series A Preferred Stock (no shares outstanding), removing designation from charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277113,"accession_number":"0001140361-23-035093","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Bionano Genomics updates legal opinion to cover up to 49M shares under ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed updated legal opinion with SEC covering sale of up to 49M shares of common stock under existing ATM facility with Cowen.","Previous opinion covered 38M shares; increase of 11M shares reflects updated capacity under $200M S-3 registration.","No changes to the Sales Agreement terms; the opinion reaffirms legality of issuance under Securities Act.","The increased share limit provides additional flexibility for potential capital raises under the existing at-the-market program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295022,"accession_number":"0001140361-23-030262","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bionano shareholders approve reverse split authorization; directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10 at board's discretion.","Proposal 4: 2.064B votes for, 1.077B against, 0.936M abstain (including Series A Preferred votes).","Elected Class II directors: Albert Luderer, Kristiina Vuori, Hannah Mamuszka for three-year terms.","Advisory vote on executive compensation passed with 28.96M for, 25.69M against.","Ratified BDO USA as independent auditor for FY2023 with 123.52M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295021,"accession_number":"0001140361-23-028021","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Bionano Genomics receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Bionano on May 30, 2023 that its common stock bid price closed below $1.00 for 30 consecutive days.","Company has 180 days to regain compliance by having closing bid price at least $1.00 for 10 consecutive business days.","If not compliant, may be eligible for additional 180-day grace period if other listing standards are met.","Stock continues to trade under symbol BNGO on Nasdaq Capital Market pending compliance.","Company intends to monitor and consider options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295020,"accession_number":"0001411690-23-000022","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano Q1 revenue $7.4M (+30% YoY); announces ~$20M cost reduction plan including layoffs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP gross margin improved to 28% from 15% YoY; non-GAAP gross margin 30%.","GAAP operating expense $39.9M; cash, equivalents and securities $95.8M (down from $113.2M).","Installed base 259 Saphyr systems (+47% YoY); 5,226 flowcells sold (+62% YoY).","Cost reduction initiative targets ~$20M savings over 4–5 quarters, includes workforce reduction effective May 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":7415000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295019,"accession_number":"0001140361-23-019943","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bionano preliminary Q1 revenue $7.3-7.5M, up 28-32% YoY; withdraws CPT code applications","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 revenue $7.3-7.5M, representing 10th consecutive YoY growth quarter.","Saphyr installed base 259 as of March 31 (+47% YoY); 19 systems added in Q1.","Preliminary flowcell sales of 5,226, up 62% over Q1 2022.","Withdraws Category I CPT code applications for OGM to avoid Category III assignment; evaluating new strategy.","Reaffirms FY 2023 guidance: revenue $35-38M and 325 OGM system installed base target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":7415000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295018,"accession_number":"0001140361-23-018454","cik":1411690,"company_name":"Bionano Genomics, Inc.","ticker":"BNGO","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","9.01"],"status":"ready","headline":"Bionano issues Series A Preferred with 3B votes to Board Chair to facilitate reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued one share of Series A Preferred to Chair David Barker for $100; share carries 3,000,000,000 votes.","Preferred votes only on Reverse Stock Split Proposal, mirroring common stock votes (excluding abstentions and broker non-votes).","Quorum requirement for stockholder meetings reduced from majority to one-third of outstanding shares.","Series A Preferred is non-convertible, ranks senior on liquidation, and will be redeemed automatically after reverse split approval.","Sale exempt under Section 4(a)(2) as accredited investor; shares cannot be transferred without Board consent prior to reverse split vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14332276.015447155,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-14T23:59:59+00:00|295018"}